Zhejiang University released the news that on March 3, the appointment ceremony of Academician Ding Jian Qiushi Chair Professor and Dean of the Cancer Research Institute of Zhejiang University was held at the Zijingang Campus.
Professor Zheng Shu, Vice Chairman of the Development Committee of Zhejiang University and former Deputy Director of the Zhejiang Provincial People's Congress, attended the ceremony; Zhou Tianhua, Vice President of Zhejiang University, welcomed Academician Ding Jian on behalf of the school, and issued him a letter of appointment from Zhejiang University and wore the school emblem.
Academician Ding Jian said that the oncology department of Zhejiang University has always adhered to the clinical orientation, and a group of experts and scholars with international academic influence have emerged, and they are willing to work with colleagues to overcome the problems of the discipline and bravely undertake the mission of the times.
Zhou Tianhua said that the joining of Academician Ding Jian will lead the Cancer Research Institute of Zhejiang University to start a new journey, create an innovative collaboration mechanism, strengthen the overall innovation and industry-research interaction of the whole chain of medical linkage, medical industry and information technology, and strive to build a highland of life and health science and technology innovation.
Jian Ding is a tumor pharmacologist, an academician of the Chinese Academy of Engineering, an academician of the Academy of Sciences of Developing Countries, and the current dean of the School of Pharmacy of the University of chinese Academy of Sciences; he has long been engaged in the research and development and personalized research of anti-tumor molecule targeted drugs, and led the establishment of an anti-tumor drug screening and pharmacodynamic evaluation system that meets international norms. In recent years, its research field has gradually expanded from the field of tumor protein kinase to emerging frontiers such as epigenetics and tumor immune microenvironment, and has laid out a four-in-one drug transformation research and development platform of "anti-tumor drug research and development - sensitive marker exploration - drug resistance mechanism exploration - combination drug program formulation".
In January 2020, focusing on the urgent needs of national strategy, the international academic frontier and the major issues facing human diseases and health, the school coordinated the development of disciplines and established the Cancer Research Institute of Zhejiang University, which will take major malignant tumor screening, early diagnosis and early treatment and early warning intervention, and tumor drug research and development as the main research directions to serve the major health needs of the country.
The relevant responsible persons of the Talent Work Office, the Academy of Science and Technology, the Medical College and affiliated hospitals, some faculties, the Professorial Committee, the Academic Advisory Committee and the cultivation team members of the Cancer Research Institute participated in the above activities.